ExeVir Bio
Jul 30, 2020
Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures
Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB's anti-tau antibody development. If everything goes according to plan, milestone payments and royalties could bring the deal's total near to USD 2 billion. Th...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
